Andrographis paniculata extract versus placebo in the treatment of COVID-19: a double-blinded randomized control trial

Puritat Kanokkangsadal , Chatchai Mingmalairak, Nichamon Mukkasombat, Pranporn Kuropakornpong, Patsorn Worawattananutai, Thana Khawcharoenporn, Intouch Sakpakdeejaroen, Neal M. Davies, Arunporn Itharat

Abstract


Background and purpose: Andrographis paniculata (Burm.f.) Nees has been recommended to relieve symptoms and decrease the severity of COVID-19. The clinical study aimed to investigate the efficacy and safety of A. paniculata ethanolic extract (APE).

Experimental approach: The efficacy and safety of APE in asymptomatic or mildly symptomatic COVID-19 patients compared with placebo were investigated through a prospective, double-blind randomized control trial. Patients received APE containing 60 mg of andrographolide, three times a day for five days. WHO progression scale, COVID-19 symptoms, and global assessment evaluated the efficacy and adverse events, liver and renal functions were monitored for safety.

Findings/Results: 165 patients completed the study (83 patients in the APE group and 82 patients in the placebo group). The highest WHO progression scale was 4 and COVID-19 symptoms were significantly relieved on the last day of intervention in both groups, with no significant difference between groups. APE significantly relieved headache symptoms on day 1 and olfactory loss symptoms on day 2 compared to placebo. The global assessment showed that 80.7% of patients had total recovery after 5-day treatment with APE. Mild diarrhea was the most common side effect with a high dose that resolved within a few days. No hepatic or renal toxicity was associated with treatment.

Conclusion and implications: APE at 180 mg/day for 5 days did not reduce COVID-19 progression in asymptomatic or mildly afflicted COVID-19 patients, however, it shortened the symptoms of olfactory loss with no adverse effects over 5 days of use.


Keywords


Capsule; Clinical trial; Coronavirus, HPLC.

Full Text:

PDF

References


Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff E J, Chiang S Agholor, et al. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021; 31(1):1-10.

DOI: 10.1002/rmv.2146.

Na-Bangchang K, Porasuphatana S, Karbwang J. Perspective: repurposed drugs for COVID-19. Arch Med Sci. 2022;18(5):1378-1391.

DOI: 10.5114/aoms/152467.

Hu XY, Wu RH, Logue M, Blondel C, Lai LYW, Stuart B, et al. Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis. PLoS One. 2017;12(8):e0181780.

DOI: 10.1371/journal.pone.0181780

Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharm. 2009;9(3):313-318.

DOI: 10.1016/j.intimp.2008.12.002.

Suebsasana S, Pongnaratorn P, Sattayasai J, Arkaravichien T, Tiamkao S, Aromdee C. Analgesic, antipyretic, anti-inflammatory and toxic effects of andrographolide derivatives in experimental animals. Arch Pharm Res. 2009;32(9):1191-1200. DOI: 10.1007/s12272-009-1902-x.

Wang W, Wang J, Dong SF, Liu CH, Italiani P, Sun SH, et al. Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response. Acta Pharmacol Sin. 2010;31(2):191-201. DOI: 10.1038/aps.2009.205.

Sa-Ngiamsuntorn K, Suksatu A, Pewkliang Y, et al. Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives. J Nat Prod. 2021;84(4):1261-1270. DOI: 10.1021/acs.jnatprod.0c01324.

Zeng B, Wei A, Zhou Q, Yuan M, Lei K, Liu Y, et al. Andrographolide: a review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches. Phytother Res. 2022;36(1):336-364. DOI: 10.1002/ptr.7324.

Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in-silico approach. J Biomol Struc Dyn. 2021;39(9):3092-3098. DOI: 10.1080/07391102.2020.1760136.

Itharat A, Tiyoa V, Sutthibut K, Ooraikul B, Davies NM. Potential Thai Herbal Medicine for COVID-19. AMJAM. 2021;21:S58-S73.

Benjaphonphithak A, Wisitthanon K, Sawangtham T, Thanirat T. Short communication on use of Andrographis herb (FA THALAI CHON) for the treatment of COVID-19 patients. J Thai Trad Altern Med. 2021;19(1):229-233.

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192-e197. DOI: 10.1016/S1473-3099(20)30483-7.

Wanaratna K, Leethong P, Inchai N, Chueawiang W, Sriraksa P, Tabmee A, et al. Efficacy and safety of Sriraksa P, Tabmee A, et al. Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: a randomized controlled trial. Arch Intern Med Res. 2022;5(3):423-427. DOI: 10.26502/aimr.0125.

Dai Y, Chen SR, Chai L, Zhao J, Wang Y, Wang Y. Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide. Crit Rev Food Sci Nutr. 2019;59(sup1):S17-S29. DOI: 10.1080/10408398.2018.1501657.

Zazhytska M, Kodra A, Hoagland DA, Frere J, Fullard JF, Shayya H, et al. Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia. Cell. 2022;185(6):1052-1064.e12. DOI: 10.1016/j.cell.2022.01.024.

Torabi A, Mohammadbagheri E, Dilmaghani NA, Bayat AH, Fathi M, Vakili K, et al. Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia. ACS Chem Neurosci. 2022;11(13):1909-1913. DOI: 10.1021/acschemneuro.0c00249.

Lu L, Ma Y, Wu J, Huang H, Wang X, Chen Z, et al. Review for the neuroprotective effects of andrographolide in the central nervous system. Biomed Pharmacother. 2019;117:109078,1-10. DOI: 10.1016/j.biopha.2019.109078.

Gabrielian ES, Shukarian AK, Goukasova GI, Chandanian GL, Panossian AG, Wikman G, et al. A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis. Phytomedicine. 2002;9(7):589-597. DOI: 10.1078/094471102321616391.

Saxena RC, Singh R, Kumar P, Yadav SC, Negi MPS, Saxena VS, et al. A randomized double-blind placebo-controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection. Phytomedicine. 2010;17(3-4):178-185. DOI: 10.1016/j.phymed.2009.12.001.

Thamlikitkul V, Dechatiwongse T, Theerapong S, C Chantrakul, P Boonroj, W Punkrut, et al. Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai. 1991;74(10):437-442. PMID: 1797953.

Panossian A, Wikman G. Efficacy of Andrographis paniculata in upper respiratory tract infectious diseases and the mechanism of action. In: Wagner H, Ulrich-Merzenich G, editors. Evidence and Rational Based Research on Chinese Drugs. Vienna: Springer; 2013. pp. 137-179. DOI: 10.1007/978-3-7091-0442-2_4.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.